Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Carvykti vs Tecvayli: how two US-approved medicines for multiple myeloma compare

Creator: Reserve Meds
Published: 2026-10-17

A side-by-side guide for families in the Gulf, built from the US FDA labels, Gulf drug registers and official sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026. Facts on this page come from the current US prescribing information for each medicine.

Carvykti vs Tecvayli: the short answer

Carvykti and Tecvayli are both US FDA-approved for multiple myeloma, but for different patients and in different ways. No trial has compared them head to head. Your specialist decides which, if either, fits. Reserve Meds is a digital health company. We do not diagnose or prescribe.

Condition: multiple myeloma.
Main difference: Both can be used after one prior line of therapy, but for different patients.
Head-to-head evidence: none in either US label.
Price: Quote on request.

Carvykti and Tecvayli side by side

The table summarizes each current US label. Labels are long; your specialist and hospital pharmacy work from the full text.

Feature	Carvykti	Tecvayli
Generic name	ciltacabtagene autoleucel^[3]	teclistamab-cqyv^[4]
Type of medicine	BCMA-directed CAR T-cell therapy made from the patient's own T cells^[3]	bispecific antibody (T-cell engager) that targets BCMA on myeloma cells and CD3 on T cells^[4]
US-approved for	Adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and whose disease is refractory to lenalidomide.^[3]	Adults with relapsed or refractory multiple myeloma, in two settings: with daratumumab and hyaluronidase-fihj after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, or alone after at least four prior lines including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.^[4]
First US approval (year on the label)	2022^[3]	2022^[4]
How it is given	One-time intravenous infusion. Lymphodepleting chemotherapy (cyclophosphamide and fludarabine daily for three days) comes first, and Carvykti is infused 2 to 4 days after it ends.^[3]	Injection under the skin by a healthcare provider. Treatment starts with step-up doses. Used alone, it continues at 1.5 mg/kg once weekly, and the dose interval may be extended to every two weeks for patients with a complete response or better for at least 6 months.^[4]
Where and what to expect	Patients are told to stay near a healthcare facility for at least 2 weeks after the infusion and not to drive for at least 2 weeks.^[3]	Patients should be hospitalized for 48 hours after step-up dose 1 and step-up dose 2, and stay near a healthcare facility with daily monitoring for 48 hours after the first treatment dose.^[4]
Boxed warning	Yes. Cytokine release syndrome, neurotoxicity (ICANS), parkinsonism and Guillain-Barre syndrome, HLH/MAS, prolonged and recurrent cytopenias, immune effector cell-associated enterocolitis, and secondary blood cancers.^[3]	Yes. Cytokine release syndrome and neurologic toxicity including ICANS. Available only through the TECVAYLI and TALVEY REMS restricted program.^[4]

About multiple myeloma and these two medicines

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell that is part of the immune system. In time, myeloma cells collect in the bone marrow and in the solid parts of bones.^[1]

Carvykti and Tecvayli both target BCMA, a protein on myeloma cells, but in different ways. Carvykti is a CAR T-cell therapy made from the patient's own T cells and given once by infusion. Tecvayli is a bispecific antibody, not made from the patient's cells, injected under the skin on a repeating schedule.^{[2, 3, 4]}

The main difference

Both can be used after one prior line of therapy, but for different patients. Carvykti is for disease that is refractory to lenalidomide after at least one prior line. Tecvayli after one prior line is given with daratumumab and hyaluronidase-fihj; used alone, it is for patients after at least four prior lines. Carvykti is a single infusion at a qualified center; Tecvayli is an ongoing injection schedule.^{[3, 4]}

The evidence behind each approval

Carvykti. CARTITUDE-4 was a randomized, open-label study in 419 adults with lenalidomide-refractory myeloma after at least one prior line. It compared Carvykti with standard therapy (DPd or PVd). The primary measure was progression-free survival, and the label reports a statistically significant improvement in overall survival at a prespecified interim analysis. CARTITUDE-1 was an earlier single-arm study.^[3]

Tecvayli. MajesTEC-3 was a randomized, open-label study in 587 patients after one to three prior lines. Tecvayli with daratumumab and hyaluronidase-fihj was compared with DPd or DVd, and the label reports a statistically significant improvement in progression-free survival and overall survival. MajesTEC-1 was a single-arm study of Tecvayli alone in 110 patients, based on overall response rate.^[4]

No head-to-head trial. Neither US label reports a study that compared Carvykti directly with Tecvayli. The trials above enrolled different patients at different stages, so their results cannot be set side by side to decide which medicine works better.

Using one after the other

Neither label reports a study of one after the other, and the MajesTEC-3 trial of Tecvayli excluded patients who had received any prior BCMA-directed therapy. Your specialist decides the order of treatments.^{[3, 4]}

Safety: what the labels warn about

Both labels list warnings that the treating team monitors. The boxed warning row in the table above is the most serious level of warning on a US label.

Carvykti: common side effects listed on the label include pyrexia (fever), cytokine release syndrome, low antibody levels (hypogammaglobulinemia), low blood pressure, musculoskeletal pain and fatigue.^[3]
Tecvayli: common side effects listed on the label include fever, cytokine release syndrome, musculoskeletal pain, injection site reactions, fatigue, upper respiratory tract infection, nausea and headache (when used alone).^[4]

Availability in the Gulf

Carvykti: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Jordan
Tecvayli: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Iraq

How families in the Gulf can access Carvykti or Tecvayli

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks it, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[7, 8]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

For Carvykti. CAR T-cell therapy is made from the patient's own cells, so treatment happens at a qualified treatment center that can collect the cells, give the lymphodepleting chemotherapy and manage side effects. For most Gulf families that means a referral from the treating specialist. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

A US safety program applies. In the US, Tecvayli is available only through the TECVAYLI and TALVEY REMS, a restricted program.^[4] The treating hospital must be able to give the step-up doses with hospital monitoring as the label describes.

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only and we do not choose between medicines.

Ask us about Carvykti or Tecvayli

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Which is better, Carvykti or Tecvayli?

There is no head-to-head trial, so no one can say from the evidence that one is better. They are approved for different patients and are given differently. Your specialist decides which fits, based on prior treatment, test results and overall health.

What is the main difference between Carvykti and Tecvayli?

Are Carvykti and Tecvayli available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list.

How can a family in the Gulf get Carvykti or Tecvayli?

Ask the treating hospital about local supply first. If the medicine is not registered, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy. CAR T-cell therapy is given at a qualified treatment center after a specialist referral.

How much do these medicines cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds choose the medicine?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or choose between medicines. Your specialist and hospital make the medical decisions.

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.